Navigation Links
Press statement on new CDC MMWR on Klebseilla pneumonia Carbapenemase-producing organisms
Date:3/18/2009

The Centers for Disease Control and Prevention (CDC) today released new infection control recommendations on Klebseilla pneumoniae Carbapenemase (KPC)-Producing Organisms, one of the most treatment-resistant gram-negative bacterium. Recent studies have shown that infections with these highly resistant bacteria are a growing problem in health care settings. In Guidance for Control of Infections with Carbapenem-Resistant or Carbapenemase-Producing Enterobacteriaceae in Acute Care Facilities published in the MMWR, CDC recommends an aggressive infection control approach to limit the emergence of these organisms.

Below Are Quotes from Mark Rupp, MD, President of SHEA

"The new guidelines highlight the need to educate clinicians and public health professionals about the importance of screening for Klebsiella pneuomoniae Carbapenemase (KPC)-Producing Organisms. If hospitals follow the CDC guidelines to detect and identify Klebsiella and Carbapenemase, then we can potentially halt the transmission of a highly treatment-resistant Gram-negative organism and prevent a large scale public health problem.

While KPC is still rare and occurs only sporadically in most parts of the country, an aggressive infection control approach needs to be taken now. These new guidelines suggest that facilities start by checking microbioloigy results for the last six to twelve months. Facilities finding evidence of these organisms should conduct a focused risk assessment or examine high-risk wards including intensive care units to make sure there is no evidence of ongoing transmission. The strategy for testing uses a selection process to get rid of most other organisms and focuses on the ones that are likely to be treatment-resistant including Carbapenem resistant Klebsiella.

For example, Israel has had widespread public health problems with these organisms, yet has managed to contain them in a short time period by implementing targeted screening and prevention practices.

The focused screening is important because there is a need to be both proactive in preventing the spread of KPCs yet judicious and mindful of limited hospital resources."


'/>"/>

Contact: Sharon Reis
sreis@gymr.com
202-745-5103
Society for Healthcare Epidemiology of America
Source:Eurekalert

Related biology news :

1. Regulatory molecule for tumor formation or suppression identified by Singapore, US researchers
2. American Chemical Societys weekly PressPac -- March 11, 2009
3. New tracking tags are providing fish-eye views of ways to manage depressed fisheries
4. Is it really only our kidneys that control blood pressure?
5. Researchers take first look at the genetic dynamics of inbreeding depression
6. Study suggests salt might be natures antidepressant
7. Children seriously affected when a parent suffers from depression
8. Chantix side effects no worse with depression history
9. Suppressing cancer with a master control gene
10. Press statement on new CDC MRSA study from SHEA president
11. Molecule that suppresses immune response under study in type 1 diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... area for financial services, but it also plays a fundamental ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... ... Parallel 6 , the leading software as a service (SaaS) provider ... Patient Encounter CONSULT module which enables both audio and video telemedicine communication between the ... the CONSULT module, patients and physicians can schedule a face to face virtual patient ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
Breaking Biology Technology: